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Abstract
Cytokines are a class of pro-inflammatory immune responses in the peripheral and central nervous system. 
Elevated cytokine levels contribute to appetite and weight dysregulation, anxiety, depression and other psychiatric 
conditions, and may underlie eating disorder (ED). Recently, two meta-analyses of cytokine levels in people with 
EDs – particularly anorexia nervosa (AN) – confirm elevated levels of cytokines within the 5-LOX inflammatory 
pathway, namely interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α). IL-1, IL-6 and 
TNF-α are leukotrienes that stimulate the prolonged response of nuclear factor kappa beta (NF-κβ) – the major 
inflammatory gateway molecule – which influences brain development and function within the hypothalamic-
pituitary-adrenal (HPA) axis, hippocampus and prefrontal cortex.  The structure and function of these brain areas 
are shown to be aberrant in neuroimaging studies of EDs; thus, neuroinflammatory processes are significant 
biomarkers for weight and cognitive disturbances in EDs, particularly AN.  Against this background, this brief article 
summarises the current knowledge of IL-1, IL-6 and TNF-α in EDs.  Thereafter, the significance of inhibiting the 
NF-κβ 5-LOX inflammatory pathway with a low-risk, Cochrane-reviewed, anti-inflammatory known as Boswellia 
serrata is considered.  Brief discussion of the clinical role for Boswellia serrata in weight recovery and reduction of 
comorbid mental disorder in ED is provided to stimulate further research into natural anti-inflammatory treatment 
interventions.
Keywords: Anorexia nervosa; Cytokines; Anti-inflammatory; NF-
kb; 5-LOX; Treatment resistance
Introduction
Two meta-analyses have recently confirmed elevated cytokine levels 
– specifically leukotrienes – in eating disorders (ED) with a genome-
wide association reported in anorexia nervosa (AN) [1-3]. EDs have 
dysregulated appetite, weight disturbance and cognitive dysfunction at 
the core [4].  Common comorbidities in EDs include anxiety, depression 
and mood disorders that are similarly linked to aberrant cytokine levels 
[5].  As such, cytokines are significant biomarkers for neuropsychiatric 
and physical disturbances in ED. Cytokines are a broad class of pro-
inflammatory molecules released by various cells in the body and 
brain, including macrophages, microglia and astrocytes [6]. Cytokines 
called prostaglandins are synthesized from arachidonic acid (AA) by 
cyclooxygenases (COX), which are inhibited for acute pain relief by 
traditional non-steroidal anti-inflammatory drugs (NSAIDs) but are 
also linked to significant gastro-intestinal complications.  Conversely, 
leukotrienes are synthesised from AA by 5-lipoxygenases (5-LOX) 
producing cytokines such as interleukins (IL) and tumour necrosis 
factor alpha (TNF-α). Given the involvement of leukotrienes in 
various psychiatric disorders – particularly EDs – 5-LOX inhibitors are 
therefore a viable target for novel psychiatric treatment development 
[7]. However, despite the link between elevated leukotrienes and EDs 
– particularly in relation to chronic weight loss and appetite restriction 
in AN – 5-LOX inhibitors have not yet been explored for their potential 
to abate clinical symptoms.
Literature Review
ILs are produced by, but also trigger the pro-inflammatory 
signalling molecule nuclear factor kappa beta (NF-κβ), which interacts 
with other intra-cellular inflammatory processes between the cellular 
membrane (e.g. from AA cleaving) to the nuclear membrane (e.g. 
genetic signalling molecules).  ILs trigger – in a feedback loop – the 
‘canonical’ inflammatory pathway leading to activation of protein 
complexes, which cause NF-κβ to translocate across the nuclear 
membrane, genetically upregulating the inflammatory response [8]. 
In turn, triggering of NF-κβ leads to the release of lymphocytes, local 
tissue destruction, antibody production, and fever, and upregulation of 
AA for a chronic inflammatory response.  Similarly, TNF-α – another 
cytokine in the 5-LOX pathway – activates vascular endothelium to 
increase permeability of vessels thought to underlie the ‘leaky-gut’ 
syndrome.  Within the leaky-gut hypothesis, lipopolysaccharide (LPS) 
might play a role as a potent inflammogen, found in the bacterial 
membrane that leaks through the gut to other peripheral and central 
nervous system regions, potentiating systemic inflammation and 
increased gut-brain porosity [9].  
Symbiosis between IL-6 and NFκβ may drive neuroinflammatory 
processes when crossing the blood-brain barrier, altering neurogenesis 
of neurons and glial cells, functioning akin to neurotrophic factors, 
and playing a major role in many psychiatric disorders [10-12]. 
Moreover, chronic elevated levels of IL-6 may have a detrimental 
effect, particularly with a longer duration of illness, on blood-brain 
barrier integrity and function.  Chronic neuroinflammation may lead 
to a ‘leaky-brain’ permeability, such that inflammatory molecules 
may better infiltrate the structure and function of brain regions, in 
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particular, hippocampus, hypothalamus and cortex [5].  Similarly, 
genetic risk for increased expression of TNF-α alters cortical brain 
volume in psychiatric disorders such as major depression, which is 
often co-morbid with AN [13].  
The expression of 5-LOX cytokines, particularly IL-6 and TNF-α in 
neuronal cells of the prefrontal cortex, hypothalamus and hippocampus 
may be associated with physical and mental disorder in EDs [1,2].  As 
such, the 5-LOX inflammatory pathway may provide a viable target for 
the development of anti-inflammatory adjuncts to treatment for EDs 
[7]. And if 5-LOX inhibitors do indeed lead to a significant reduction in 
ED symptoms, this may increase knowledge as to the neurobiological 
mechanisms of EDs, providing novel biomarkers for further treatment 
development. To date, however, no group studies have examined 
the clinical benefits of cytokine inhibition in AN, and none targeting 
the 5-LOX inflammatory mechanisms in AN.  Only one case study 
of a single AN patient has reported the beneficial effects of a TNF-α 
antagonist on depression [14].  A larger study – though not in EDs 
– following this line of thought has shown that TNF-α suppressing 
medication increases body weight in chronic inflammatory diseases 
[15].  And while AN patient’s report feeling uncomfortable about 
weight gain during treatment, weight gain is an essential part of medical 
improvement, although cytokine inhibitors may also lower anxiety and 
depression, which would likely be welcomed by AN patient [16].
Against this background, next follows a brief summary of the meta-
analyses of cytokine levels in ED to provide a foundation for exploring 
the hypothesis that cytokine – particularly 5-LOX – inhibitors are a 
viable target for treatment-resistant AN.  In particular, a specific 5-LOX 
inhibitor, namely the low-risk – according to two recent Cochrane 
reviews– nutritional supplement anti-inflammatory Boswellia serrata 
will be briefly reviewed [17-22].  
Additionally, a brief description of the biological mechanisms of 
action of the 5-LOX pathway – including NF-κβ in relation to ILs and 
TNF-α is given, to aid understanding of the link between EDs, 5-LOX 
inhibitors and novel treatment development. 
Summary of meta-analyses of cytokine levels in eating 
disorders
The first meta-analysis of cytokine levels in EDs was published 
by Solmi and colleagues in 2014, which included cross-sectional and 
longitudinal studies of adults with AN. Compared to healthy controls 
(HC), currently-ill, underweight AN patient in treatment had elevated 
levels of the leukotrienes: IL-1, IL-6, TNF-α and TNF-receptor-II. 
Conversely, AN patient had significant decreases in C-reactive protein 
(normally associated with higher levels of adiposity and overweight) in 
comparison to HCs [2].  Furthermore, the IL-6 receptor was reported 
to be downregulated in AN compared to HC, with no differences in 
TNF-receptor I and transforming growth factor (TGF)-β.  In additional 
longitudinal study analyses – of which there were significantly fewer 
– Solmi and colleagues showed that acute weight gain (e.g. during 
treatment) was not associated with significant changes in levels of 
TNF-α, IL-6 and IL1-β.  However, after a sustained period of weight 
gain after treatment, IL-6 levels in AN patient normalised in line with 
the levels observed in HC.  Meta-regression analyses further revealed 
that shorter illness duration in those with AN, but not younger age, 
significantly moderated higher IL-6 levels.  
Progressing Solmi et al.’s work five years’ later; Dalton and 
colleagues extended the meta-analyses of cytokine levels in all types of 
EDs, and additionally included new studies up to May 2018 [1]. On the 
basis of the previous data, Dalton and colleagues focused on IL-1, IL-6, 
TNF-α and TGF-β levels only.  Dalton and colleagues confirmed that 
IL-6 and TNF-α were significantly elevated in cross-sectional studies 
of all EDs compared to HCs, which appeared to be driven by the AN 
versus HC contrast (there were only four studies of bulimia nervosa 
[BN]).  Taken together, these two meta-analyses highlight that extreme 
appetite restraint and acute weight loss in AN is linked to elevated levels 
of cytokines, especially the leukotrienes IL-6 and TNF-α.  Moreover, 
there is some evidence that only sustained – and not acute – weight 
increases are associated with normalisation of these pro-inflammatory 
molecules.
Mechanisms of action of NF-κβ in relation to IL-1, IL-6, 
TNF-α and 5−LOX inflammatory pathways
The NF-κβprotein complex involves Class I and II proteins within a 
canonical/classic, and a non-canonical pathway. NF-κβ resides within 
mammalian cell cytoplasm, activates via the metabolism of NF-κβ 
inhibitors, and is the rapid response of the cell to various pathogens. 
A feedback loop via increased expression of IL-1, IL-6 and TNF-α, and 
the receptor activator of NF-κβ RANK) – a type of TNF-α receptor 
-maintains chronic activation of NF-κβ and a sustained inflammatory 
response [10]. In an unstimulated state, NF-κβ remains inactive in 
the cell cytoplasm, inhibited by inhibitors of κB (Iκβs) that mask the 
nuclear localization signals (NLS), preventing the NF-κβ translocation 
cascade across the nuclear membrane.  However, when degradation 
of the protein Iκβs via phosphorylation and ubiquitination occurs, 
the NF-κβ protein complex is free to translocate across the nuclear 
membrane, docking at a gene promotor region for transcription of 
inflammatory molecules.  
NF-κβ becomes activated when, for example, its receptor-ligand 
complex (e.g. RANKL) is stimulated by reactive oxygen species (ROS), 
ionizing radiation, bacterial LPS, stimulant drugs such as cocaine 
and methamphetamine, and inflammatory molecules such as ILs 
in a chronic feedback loop [23].  Subunit molecules residing in the 
mammalian cell cytoplasm, such as p50 and p52 mediate NF-κβ targeted 
gene transactivation by forming heterodimers with RelA, RelB, or c-Rel 
[24]. All proteins of the NF-κβ family share a Rel homology in their 
N-terminus.  However, in the non-canonical/alternative pathway, the 
p50 and p52 proteins in the Class I NF-κβ cascade is not able to activate 
genetic transcription on their own, but rather function as transcription 
repressors while binding to the κβ proteins.  As such, when the p50 and 
p52 proteins are phosphorylated, NF-κβ becomes activated. Conversely, 
the Class II protein subfamily of NF-κβ, including RelA, RelB, and 
c-Rel, have the transactivation domain at their C-terminus and are 
able to directly translocate to the nuclear membrane.  When the NF-κβ 
complex is activated by one of these routes, it enters the cell nucleus 
to influence the expression of various genes. The most common result 
of NF-κβ activation of these genes are physiological responses such as 
an immune/inflammatory response, cell proliferation or cell survival. 
However, NF-κβ also influences central nervous system processes, such 
as glutamate, and brain-derived neurotrophic factor (BDNF) mediated 
synaptic plasticity, learning and memory [25].
The classical/non-classical NF-κβ nuclear translocation pathway 
stimulates gene transcription of various cytoplasmic enzymes 
such as COX and 5-LOX. The NF-κβ-production of COX enzymes 
is responsible for the metabolism of AA into pro-inflammatory 
molecules such as prostaglandins.  Conversely, the NF-κβ-production 
of 5-LOX enzymes is responsible for the metabolism of AA into pro-
inflammatory leukotrienes, such as IL-1, IL-6, TNF-α (which are able 
to activate RANK for chronic NF-κβ activation).  Commonly-used 
non-steroidal anti-inflammatories (NSAIDs) – including ibuprofen 
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particular, increased concentrations of TNF-α coincide with anxiety, 
depression and obsessive-compulsive disorder, which are often co-
morbid with EDs [46,47]. As such, IL-6 and TNF-α appear to interact 
with brain processes (e.g. hypothalamic networks) responsible for 
feeding and weight regulation, psychological distress and anxiety, 
which has a direct link to chronic activation via the specific receptor-
ligand complex RANK.  This is particularly pertinent, given that genetic 
risk for increased TNF-α expression is associated with reduced angular 
gyrus and visual cortex volume– brain regions that underlie variance in 
cognitive control of body weight and feeding in EDs [48-50].
Elevated levels of ILs, TNF-α and NF-κβ are also associated with 
psychiatric comorbidities in AN and appear to have a genetic link, 
including anxiety, depression, mood and addictive disorders [51-55]. 
Anxiety is associated with hippocampal synaptogenesis and elevated 
levels of NF-κβ are demonstrated by animal models of social isolation 
and stress [56,57].  Human studies of anxiety corroborate the role of 
increased inflammatory markers, and in relation to the role of NF-κβ 
in learning, memory and synaptogenesis [25,58].  Similarly, in human 
studies of depression, an interaction between the glucocorticoid 
receptor complex and NF-κβ underlies the neuroexcitoxic effects 
of chronic stress [59]. Moreover, bipolar and other mood disorders 
often observed in those with EDs are successfully targeted to improve 
symptoms by suppression of the AA pro-inflammatory pathways [60]. 
Finally, elevated levels of NF-κβ are typically observed in addictive 
disorders, and recent advances in the understanding of neural 
processes underlying AN has led to habitual appetite restraint under 
risky circumstances (e.g. potentially fatal weight loss and related health 
consequences) being regarded as an addiction process [61]. 
Inhibition of the NF-κβ/5−LOX pathway with a low-risk, 
Cochrane-reviewed, anti-inflammatory: potential novel 
intervention for EDs?
Against this background, is seems plausible that inhibition of the 
NF-κβ/5-LOX pro-inflammatory pathway – particularly related to 
extreme upregulation of IL-6 and TNF-α – may improve disrupted 
feeding behaviour, weight loss and neuropsychiatric effects in EDs, 
especially AN.  However, caution is needed when considering 5-LOX 
inhibitors as a clinical adjunct, given that excessive or prolonged NF-
κβ/5-LOX inhibition may compromise the immunological response 
to pathogens.  For example, chronic use of NSAIDs, which are COX 
inhibitors, may be associated with alternate processing of AA into 
5-LOX leukotrienes [62].  As such, inhibition of the 5-LOX pathway 
may similarly lead to alternate processing of AA into COX-mediated 
prostaglandin expression and increased pain, swelling and fever.  As 
for immunosuppression therapy for various physical illnesses (e.g. 
cancer, inflammatory conditions), a compromised immunological 
response may increase susceptibility for infection in those with EDs. 
That said, two recent Cochrane reviews of a natural anti-inflammatory 
nutritional supplement described below did not report compromised 
immunological responses following its use [17,18].  This is probably 
because certain disorders, including EDs, already have maladaptive 
and excessive levels of pro-inflammatory molecules that need to be 
reduced.  Furthermore, as described below, certain 5-LOX inhibitors 
may rather target a specific inflammatory cascade as opposed to the 
total NF-κβ response, and as such, may not interfere with the general 
and rapid inflammatory response to pathogens.
The next logical question is whether any candidate NF-κβ/5-LOX 
inhibition compounds that avoid the gastrointestinal and cardiac 
adverse effects of NSAIDs are currently being studied in those with Eds 
[63].  To date, it appears that one case study has examined the effects of 
and aspirin – inhibit the enzymatic activity of the COX prostaglandin 
system for acute pain relief for example.  In contrast, other natural 
anti-inflammatories, such as nutrients in ‘Mediterranean diet’ foods, 
(e.g. Olive Oil, resveratrol/red wine) and dietary supplements (e.g. 
Curcumin and Boswellia serrata -specifically the active triterpenoid 
compound acetyl-11-keto-β –boswellic acid; AKβA) may preferentially 
inhibit the 5-LOX pathway [19-22,26].
What is the significance of inhibiting 5-LOX and IL-1, IL-6 
and TNF-α in EDs?
Improved understanding of the pathophysiology of EDs is urgently 
needed, given that efficacious psychopharmacological interventions 
are limited, and that approximately half of ED patients relapse after 
standard treatment [27-30]. Thus, turning to the mechanisms of 
cytokine action – particularly within the 5-LOX pro-inflammatory 
pathway in light of the recent meta-analyses– may prove fruitful for 
novel treatment development [1,2].  
Animal models of disrupted feeding demonstrate that elevated 
levels of ILs are part of the neuroinflammatory pathway within the 
hypothalamus, interacting with hypothalamic pro-opiomelanocortin 
(POMC) and neuropeptide Y (NPY) neurons to influence peptide 
release such as leptin (the ‘satiety’ molecule) and ghrelin (the ‘appetite’ 
molecule).  For example, animal studies have implicated increased 
levels of IL-1β in reduced meal size and eating duration, but not meal 
frequency or reduced food-seeking behaviour [31,32]. Similarly, IL-6 
interacts with hypothalamic leptin expression to reduce appetite 
and decrease body fat in animal studies, engaging similar auxiliary 
signalling molecules to leptin in the hypothalamus and forebrain to 
suppress appetite, although the exact mechanism of action of ILs on 
peptide expression is unclear.  Moreover, animal models of stress show 
hyper-release of pro-inflammatory cytokines during acute and chronic 
stress, implicating the modulation of hypothalamic-pituitary-adrenal 
(HPA) axis function that plays a major role in EDs [33-39].
Additionally, TNFα and IL-6 together disrupt the function of 
hypothalamic cells and in mice models, altering serotoninergic 
metabolism and causing reduced food intake [40].  
The role of the hypothalamus in appetite regulation is well-
established, with reciprocal pathways to higher cortical brain regions 
that bi-directionally modulate feeding behaviour.  For example, the 
arcuate nucleus has populations of neurons that when stimulated 
induce satiety (ventral medial region) or hunger (lateral region) 
and interact directly with released gut hormones, and inflammatory 
molecules [41,42]. Moreover, LPS the potent inflammogen that forms 
part of microbiome bacterial cell walls, when injected directly into the 
hypothalamus in animal models reduces feeding and stimulates weight 
loss in line with elevated IL-1β levels [43]. Finally, there is significant 
evidence that increased levels of these 5-LOX pro-inflammatory 
cytokines contribute to osteoporosis in females with AN [44]. Taken 
together, neuroinflammatory processes may contribute to a ‘leaky’ 
blood-brain barrier as well as mental and physical disorder in Eds [5].
In terms of the role of TNF-α in EDs, the latest meta-analysis of 
cytokines found a trend for elevated levels in BN but the small number 
of studies included (n = 3) prevented definitive conclusions [1].  TNF-α 
is suggested to be involved in the acute-response to trauma and threat, 
is secreted into the blood stream following an immunological challenge 
and activates NFκβ via RANK. TNF-α is released by macrophages, 
natural killer cells and T-cells to induce fever [45]. Psychological 
distress is significantly linked to elevated release of cytokines, and in 
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a 5-LOX inhibitor, namely a TNF-α antagonist (infliximab) prescribed 
for Crohn’s Disease appearing at age 24, in a 26-year-old female 
patient who had experienced AN since age 14 [14]. Crohn's disease can 
exacerbate AN by altering hunger and energy metabolism via altered 
levels of TNF-α and IL-6, which moderate leptin and melanocortin 
signalling in the hypothalamus [14].  In this case study, the TNF-α 
antagonist improved the patient’s eating behaviour, weight status 
and psychopathy (anxiety, depression and engagement in cognitive 
behavioural treatments) over approximately 6 months. However, no 
case versus control studies have yet been conducted to examine the 
effects of NF-κβ/5-LOX suppressant compounds on ED symptoms.
Discussion
Given that traditional NSAIDs, which have adverse effects, target 
the COX pro-inflammatory pathway, a non-NSAID 5-LOX inhibitor 
is rather preferable to test the effects on pro-inflammatory leukotriene 
levels in Eds [19].  One such nutritional supplement anti-inflammatory 
exists – Boswellia serrata (its active ingredient being AKβA), which 
may preferentially inhibit the 5-LOX pathway.  For example, Boswellia 
serrata appears to specifically inhibit the expression of 5-LOX 
inflammatory molecules by disrupting upstream inhibitor kinases 
of kappa beta (IKK), processes that regulate the ability of NF-κβ to 
translocate through the nuclear membrane to influence leukotriene-
related gene transcription [20,64-66]. However, conflicting data exists 
that instead of inhibiting the 5-LOX pathway, Boswellia serrata might 
rather inhibit cathepsin G (catG) and microsomal prostaglandin 
E synthase (mPGES)-1 [67].  The mPGES-1 system is an interesting 
mechanism of action to consider, given that mPGES-1 is implicated as 
a mediator of inflammatory induced AN in certain mice strains [68]. 
Furthermore, studies have shown that Boswellia serrata intercepts 
IKK function, preventing the degradation of the NF-κβ inhibitor 
IrK, and thus preventing phosphorylation of p65, essential for NF-κβ 
activation and downstream cytokine expression [69,70].  Inhibition of 
IKK distinguishes Boswellia serrata from other nutritional compounds 
(e.g. Olive Oil, resveratrol) that appear to exert their effects upstream 
of the IKK, and which are not reported to significantly compromise 
(in fact might rather enhance, according to statistics on the related 
benefits of the Mediterranean diet) immunity [71,72]. However, the 
exact mechanism of action of Boswellia serrata is yet to be clarified, 
although it does appear to broadly alter – or downregulate – the 
excessive inflammatory response of NF-κβ and its ability to translocate 
across the nuclear membrane.  This in itself is of interest – given that 
elevated IL-6 levels are related to NF-κβ function– for molecular-based 
treatment of AN [10].
In support of its use as a safe anti-inflammatory nutritional 
supplement, Boswellia serrata has been clinically examined in two 
recent Cochrane reviews, albeit in studies of people with physical 
inflammatory illnesses (e.g. arthritis, colitis, asthma, cancer) and 
not psychiatric disorders [17,18].  The reviews report that Boswellia 
serrata warrants further exploration, with some evidence of its 
clinical benefit for reducing excessive inflammation alongside low/
rare adverse reactions and significantly reduced leukotriene and 
NF-κβ levels.  Additionally, there is some indication that Boswellia 
serrata might be slower-acting than traditional NSAIDs and so cross-
sectional studies over a short duration must consider the potential 
to commit false negatives, which may prompt future longitudinal 
analyses [73,74]. Moreover, the concentration of the active ingredient 
– AKβA – in Boswellia serrata is highly variable and not adequately 
reported in currently marketed brands [74].  However, there is good 
evidence that one brand available on the market consistently provides 
the recommended daily dosage of 28-30% AKβA per 100 mg tablet, 
although it is still traditionally farmed (e.g. gum resin drawn from tree 
bark), which is unlikely to provide long-term clinical sustainability [75]. 
In light of this, laboratories are attempting to synthesise compounds 
that mimic Boswellic acid (AKβA), although this research has a 
long way to go before providing marketable products fit for human 
consumption [76].  However, the currently available Boswellia serrata 
products that have been scientifically tested include 5-Loxin® (90 days, 
100 mg/250 mg); Aflapin® (100 mg for 30 days); Boswellin® (150 mg 
daily); Casperome® (dose not known); Curamin® (450 mg for 90 days); 
Eumastós® (dose not known); H15® (single 800 mg dose); Phytoproflex® 
(dose not known); Shallaki® (single 125 mg dose). 
Boswellia serrata has only been experimentally tested in physical 
disorders, with significant beneficial effects and reduced 5-LOX 
cytokine levels reported [17,18].  However, given the comparable link 
between elevated 5-LOX cytokines, namely IL-1, IL-6 and TNF-α and 
psychiatric disorders, particularly EDs, there is good reason for further 
exploration of Boswellia serrata in Eds [7].  The justifications for testing 
Boswellia serrata in ED patients to reduce ED symptoms, stimulate 
weight gain, and improve psychiatric comorbidities are broad.  
First, Boswellia serrata induces emmenagogue (promotion of 
menstrual flow, a danger for women seeking to get pregnant), whereas 
ammenohorea (lack of menstruation) is a major symptom of chronic 
AN associated with hypothalamic dysfunction that sometimes persists 
after weight gain [77,78], suggesting that Boswellia serrata interacts 
with hypothalamic inflammatory processes.  Second, Boswellia 
serrata appears to preferentially inhibit 5-LOX cytokines over COX 
cytokines, particularly with regard to preventing phosphorylation of 
non-canonical NF-κβ subunits at a lower dose within the 100-250 mg 
range for a daily dose of Boswellia serrata enriched with 30% AKβA 
[19-22,76,77]. However, caution must be taken with higher doses that 
might be excessively immune-stimulatory or toxic [78-80]. Third, 
studies (mainly in animals) have demonstrated significant 5-LOX 
cytokine reduction following Boswellia serrata administration.  For 
example, Boswellia serrata inhibits LPS-mediated TNF-α induction in 
monocytes by direct interaction with NF-κβ Iκβ kinases and miRNA 
[81]. This is pertinent when considering AKβA/Boswellia serrata as 
an adjunct to treatment for AN, given that LPS induction into the 
hypothalamus can induce the release of leptin and AN symptom 
[12,11].  And also, that AN is associated with significantly high levels 
of interleukins – particularly IL-6 – including TNF-α, the latter may 
specifically activate NF-κβ via the receptor-ligand complex RANKL [1,2].
Concluding Remarks
Relapse rates in EDs are high and account for approximately half 
of patient’s post-treatment, with current psychopharmacological 
interventions limited by their efficacy and availability.  As such, the 
clinical implications are that novel adjuncts to standard treatment 
addressing molecular and genetic neuropathology of EDs are 
urgently needed.  Two recent meta-analyses have shifted the 
focus of neuropathology of EDs towards a molecular and genetic 
perspective, reporting increased levels of 5-LOX ILs, particularly IL-6 
and TNF-α that interact with NF-κβ to form a significant chronic 
pro-inflammatory response (e.g. a ‘leaky gut’ and ‘leaky brain’). 
Permeability within the gut may allow LPS within bacteria to infiltrate 
the peripheral immune system, triggering NF-κβ, IL-6 and related 
molecules.  Permeability within the blood-brain-barrier may allow for 
the passage of 5-LOX cytokines that may preferentially, or at a higher 
concentration threshold (e.g. according to genetic susceptibility), target 
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hypothalamic, hippocampal and prefrontal cortex memory networks, 
resulting in disrupted feeding behaviour.  Disrupted feeding behaviour 
may in turn exacerbate the chronic inflammatory process in the gut 
and brain, permeating the structure and function of neurotransmitter 
and hormone signalling networks.  This may lead to ED-comorbid 
disorders including anxiety, depression, obsessive-compulsivity and 
addictive disorder.  
A 5-LOX inhibitor reduces levels of NF-κβ and therefore ILs 
– particularly IL-6 and TNF-α The clinical relevance of this is that 
5-LOX inhibition might beneficially alter the function of pro-
inflammatory cytokines within the neural circuitry (e.g. involving 
the hypothalamus, hippocampus, prefrontal cortex) underlying the 
physical and psychological symptoms of EDs (e.g. weight loss, appetite 
restraint, anxiety, depression, cognitive dysfunction).   Boswellia 
serrata (its active ingredient being AKβA) is a nutritional supplement 
that specifically appears to disrupt the 5-LOX cytokine intracellular 
pathway, by preventing the phosphorylation of NF-κβ, and is low risk 
according to two recent Cochrane Reviews. However, no studies have 
yet examined the inhibiting effect of Boswellia serrata on NF-κβ and 
subsequent benefits in psychiatric disorders, including AN, which is 
most significantly associated with elevated IL-6 levels.  To justify the 
exploration of Boswellia serrata supplementation in AN, animal studies 
have demonstrated that AkβA inhibits LPS-mediated TNF-α induction 
in monocytes by direct interaction with NF-κβ Iκβ kinases and 
miRNA.  This is pertinent in that LPS induction into the hypothalamus 
can induce the release of leptin and AN symptom and AN is associated 
with significantly high levels of IL-6 TNF-α.  Thus, now is the time 
for careful selection of Boswellia serrata products currently available 
as nutritional supplements, based on existing scientific evidence.  This 
is to probe the clinical relevance of Boswellia serrata supplementation 
during AN treatment for improving feeding and weight status, 
reducing anxiety, depression and cognitive dysfunction, and ultimately 
a significant reduction in long-term relapse rates.
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